News Story: Full Text
Sponsored By
Genentech Biooncology
Please Click On The Above Banner For More Details
Braintumor Website


The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy.

Al's Comment:

 Interesting article.  It says that the addition of Temodar at the same time (and after) as radiation (which is now the standard of care) does NOT change the pattern of recurrence.  Most (91%) had recurrence in the same area as the original tumor which is about the same as when they used Temodar only after radiation.  The significance is this may mean widening the area radiated won't make much difference.

Posted on: 10/10/2012

J Med Imaging Radiat Oncol. 2012 Oct;56(5):567-73. doi: 10.1111/j.1754-9485.2012.02414.x. Epub 2012 Jul 25.

The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy.

Gunjur A, Bressel M, Ryan G.
Faculty of Medicine, Dentistry and Health Sciences, the University of Melbourne, Melbourne, Victoria, Australia.

To determine whether the pattern of progressive disease (PD) for glioblastoma multiforme (GBM) patients has changed with the introduction of the current standard of care protocol - postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose (75-100 mg/m(2) ) temozolomide, followed by six cycles of adjuvant high-dose (150-200 mg/m(2) ) temozolomide - as compared with radiotherapy alone.

For GBM patients commencing combined modality treatment between October 2005 and August 2009, the MRI scan confirming progression (if any) was co-registered with the original planning CT scan, and progression site(s) marked. Coverage of the composite progression volume (PDvol) by the original 95% prescription isodose volume was obtained from dose-volume histogram (DVH) data, and assigned as 'central', 'in field', 'marginal' and 'out of field', corresponding to >95%, >80%, 20-80% and <20% coverage.

Of 68 consecutive patients identified, 54 (79.4%) had documented PD. Of the 47 (87%) evaluable patients, 43 (91%) had in field progression with 36 (77%) of these being central. Of the remaining four cases, three (6%) had marginal progression, and only one patient (2%) had out of field progression. Median overall and progression-free survival were 11.6 and 6.6 months, respectively.

The pattern of progression in our GBM patients does not appear to have been altered by the addition of temozolomide. The overwhelming majority of first PD occurred within the original radiotherapy planning target volume, as is the case in patients treated with radiotherapy alone. Major changes to radiotherapy volumes are not indicated, with alternative strategies required to improve outcomes.


Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557